Attenuation of liver stiffness in sorafenib-treated patients with advanced hepatocellular carcinoma
نویسندگان
چکیده
1Department of Radiology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Linkou Medical Center, Taoyuan 333, Taiwan. 2Department of Surgery, Xiamen Chang Gung Hospital, Xiamen 361000, Fujian, China. 3Department of Surgery, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Linkou Medical Center, Taoyuan 333, Taiwan. 4Department of Nuring, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan 333, Taiwan. 5Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan 333, Taiwan. *Authors contributed equally to this study.
منابع مشابه
The effect of nanomicelle curcumin, sorafenib, and combination of the two on the cyclin D1 gene expression of the hepatocellular carcinoma cell line (HUH7)
Objective(s): Hepatocellular carcinoma (HCC) is one of the most significant health condition around the world. As the only curative therapies, liver transplantation and surgical resection are the clinical treatments of HCC. Due to the systemic toxicity and severe side effects of these treatments, it is vital to establish new therapeutic approaches. The present study ai...
متن کامل“ TACE with drug - eluting beads is a safe treatment option ” In patients with advanced hepatocellular
The study, published in the Journal of Vascular and Interventional Radiology, was focused on investigating TACE with drug-eluting beads (Biocompatibles) in patients with Barcelona Clinic Liver Cancer (BCLC) C stage hepatocellular carcinoma. The recommended treatment for advanced stage hepatocellular carcinoma was systemic therapy. The authors noted that, until the SHARP (Sorafenib hepatocellula...
متن کاملLate-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report
INTRODUCTION In the past, no effective systemic therapy has existed for patients with advanced hepatocellular carcinoma. Sorafenib, an oral multikinase inhibitor, has recently been shown to improve overall survival in patients with advanced hepatocellular carcinoma in two randomized, double-blinded, placebo-controlled trials. This drug has been approved as the first-line therapy for advanced he...
متن کاملValidation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.
BACKGROUND Transcatheter arterial chemoembolization (TACE) failure or refractoriness is an indication for sorafenib therapy in patients with advanced hepatocellular carcinoma. The study evaluated the validity of the definition of TACE failure or refractoriness as proposed by the Liver Cancer Study Group of Japan (LCSGJ) through a retrospective analysis of sorafenib treatment. METHODS Out of 2...
متن کاملAlternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study
Sorafenib is an oral multikinase inhibitor that has been approved to treat advanced hepatocellular carcinoma (HCC), though it is unclear how much benefit advanced HCC patients with progressive disease (PD) derive from sorafenib treatment. This study aimed to assess survival risk factors and evaluate therapeutic strategies for advanced HCC patients with PD after sorafenib treatment. We analyzed ...
متن کامل